Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
FDA reversal sends mixed message to multiple sclerosis community.
Moyamoya disease in a patient with neuromyelitis optica.
Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone.
Immune suppression of JC virus gene expression is mediated by SRSF1.
Demyelinating disease: Novel markers for disease severity in neuromyelitis optica.
FLT PET/CT in a Case of Demyelinating Disease.
Interferon-Beta-Induced Pulmonary Sarcoidosis in a 30 Year-Old Male With Multiple Sclerosis: A Case Report.
Design of Peptide Immunotherapies for MHC Class-II-Associated Autoimmune Disorders.
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.
Multiple sclerosis relapse phenotype is an important, neglected, determinant of disease outcome - NO.
Purinergic Signaling and the Functioning of the Nervous System Cells.
The Outlook for Alemtuzumab in Multiple Sclerosis.
[Multimodal complex treatment in advanced multiple sclerosis.]
ADvanced IMage Algebra (ADIMA): a novel method for depicting multiple sclerosis lesion heterogeneity, as demonstrated by quantitative MRI.
Switch-Associated Protein 70 Antibodies in Multiple Sclerosis: Possible Association with Disease Progression.
Dimethyl fumarate (Tecfidera) for multiple sclerosis.
[Inflammatory and autoimmune reactions in different forms of nervous system functioning disorders].
Role of SIRT1 in autoimmune demyelination and neurodegeneration.
Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy.
Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice.
MS Prevalence and Patients' Characteristics in the District of Braga, Portugal.
A spectrum of inflammation and demyelinization in acute disseminated encephalomyelitis (ADEM) of children.
Objective assessment of C-fiber function by electrically induced axon reflex flare in patients with axonal and demyelinating polyneuropathy.
The Subventricular Zone is Able to Respond to a Demyelinating Lesion after Localized Radiation.
Synergistic Interactions between Cytokines and AVP at the Blood-CSF Barrier Result in Increased Chemokine Production and Augmented Influx of Leukocytes after Brain Injury.
Pages
« first
‹ previous
…
530
531
532
533
534
535
536
537
538
…
next ›
last »